SCHEMBL15415872

SCHEMBL15415872

ClCc1nc2cc(Cl)ccc2n1C1CCOCC1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE10A Q9Y233 2/20 0.44
CYP11B2 P19099 1/20 0.44
PIK3CB P42338 2/20 0.40
JAK2 O60674 1/20 0.40
JAK3 P52333 1/20 0.40
PIK3CD O00329 1/20 0.40
CCR3 P51677 1/20 0.39
CNR1 P21554 1/20 0.38
CNR2 P34972 1/20 0.38
MCHR1 Q99705 4/20 0.38
KCNH2 Q12809 1/20 0.38
PIK3CA P42336 1/20 0.37
PIK3CG P48736 1/20 0.37
LRRK2 Q5S007 1/20 0.37
CCNC P24863 2/20 0.37
CDK8 P49336 2/20 0.37
PDE4D Q08499 1/20 0.37
ALDH1A1 P00352 1/20 0.36
POLB P06746 1/20 0.36
HTR3A P46098 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15415417 0.92 CYP11B2 (0.40) PDE10ACYP11B2PIK3CBJAK2JAK3
SCHEMBL15416560 0.86 CYP11B2 (0.41) CYP11B2PIK3CBCCR3MCHR1KCNH2
SCHEMBL16763611 0.84 CYP11B2 (0.47) CYP11B2CCR3MCHR1KCNH2EP300
SCHEMBL15416360 0.84 CYP11B2 (0.47) CYP11B2CCR3MCHR1KCNH2EP300
SCHEMBL19470911 0.83 CYP11B2 (0.46) PDE10ACYP11B2JAK2JAK3CCR3
SCHEMBL24165560 0.83 CYP11B2 (0.46) CYP11B2CCR3MCHR1KCNH2LRRK2
SCHEMBL18807889 0.82 CYP11B2 (0.43) CYP11B2CCR3MCHR1KCNH2ALDH1A1
SCHEMBL16512912 0.79 CCR3 (0.48) CYP11B2CCR3MCHR1KCNH2
SCHEMBL16763370 0.79 CYP11B2 (0.43) CYP11B2JAK2CCR3MCHR1KCNH2
SCHEMBL22495117 0.79 FPR2 (0.47) CYP11B2ALDH1A1EP300

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3728220-B1 PHARMACEUTICAL COMPOUNDS REVIRAL LTD (GB) 2022-01-05 EP disclosed
US-11141406-B2 Pharmaceutical compounds ReViral Limited (GB) 2021-10-12 US disclosed
CN-107108557-B Spirocyclic indolines for the treatment and prophylaxis of Respiratory Syncytial Virus (RSV) infection 瑞威有限公司 2020-11-10 CN disclosed
EP-3728220-A1 PHARMACEUTICAL COMPOUNDS Reviral Limited (GB) 2020-10-28 EP disclosed
US-20200316030-A1 PHARMACEUTICAL COMPOUNDS SILICON VALLEY BANK 2020-10-08 US disclosed
EP-3204375-B1 SPIRO-INDOLINES FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS INFECTION (RSV) REVIRAL LTD (GB) 2019-02-13 EP disclosed
US-10106539-B2 Spiro-indolines for the treatment and prophylaxis of respiratory syncytial virus infection (RSV) ReViral Limited (GB) 2018-10-23 US disclosed
US-20170305908-A1 SPIRO-INDOLINES FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS INFECTION (RSV) ReViral Limited (GB) 2017-10-26 US disclosed
EP-2872502-B1 NOVEL INDAZOLES FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS INFECTION HOFFMANN LA ROCHE (CH) 2016-08-24 EP disclosed
US-20160200741-A1 Novel indazoles for the treatment and prophylaxis of respiratory syncytial virus infection HOFFMANN-LA ROCHE INC. (US) 2016-07-14 US disclosed
US-9206191-B2 Indazoles for the treatment and prophylaxis of respiratory syncytial virus infection HOFFMANN-LA ROCHE INC. (US) 2015-12-08 US disclosed
US-20150158879-A1 Novel indazoles for the treatment and prophylaxis of respiratory syncytial virus infection HOFFMANN-LA ROCHE INC. (US) 2015-06-11 US disclosed
EP-2872502-A1 NOVEL INDAZOLES FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS INFECTION F. Hoffmann-La Roche AG (CH) 2015-05-20 EP disclosed
WO-2014009302-A1 NOVEL INDAZOLES FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS INFECTION F. HOFFMANN-LA ROCHE AG (CH) 2014-01-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11141406-B2 Pharmaceutical compounds CBR3, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CBR1 PDE10A 1713/4885CYP11B2 375/4885PIK3CB 4581/4885
US-20170305908-A1 SPIRO-INDOLINES FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS INFECTION (RSV) NR3C2, SAV1, ACE2 PDE10A 4824/4885CYP11B2 874/4885PIK3CB 4750/4885
US-20200316030-A1 PHARMACEUTICAL COMPOUNDS CBR3, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CBR1 PDE10A 2068/4885CYP11B2 334/4885PIK3CB 4508/4885
US-20150158879-A1 Novel indazoles for the treatment and prophylaxis of respiratory syncytial virus infection ADORA3, ADORA1, BRS3 PDE10A 4238/4885CYP11B2 526/4885PIK3CB 3660/4885
US-20160200741-A1 Novel indazoles for the treatment and prophylaxis of respiratory syncytial virus infection ADORA3, ADORA1, BRS3 PDE10A 4238/4885CYP11B2 526/4885PIK3CB 3660/4885
US-10106539-B2 Spiro-indolines for the treatment and prophylaxis of respiratory syncytial virus infection (RSV) SPTBN1, NR3C2, SPNS2 PDE10A 4848/4885CYP11B2 748/4885PIK3CB 4739/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.